Skin Cancer Diagnostics and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Skin Cancer Diagnostics and Therapeutics market is segmented by Disease Type (Melanoma, and Non-melanoma), Diagnosis, Treatment, and Geography.

Home Industry Reports Healthcare Skin Cancer Diagnostics and Therapeutics Market - Growth, Trends, COVID-19 Impac ...

Market Snapshot

Skin Cancer Diagnostics Therapeutics Market Size
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 10.4 %
Skin Cancer Diagnostics Therapeutics Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Skin cancer is the most common form of cancer. Even though most types of skin cancers are preventable, its incidence is increasing. The risk factors include sunlight, sunlamps and tanning booths, certain medical conditions, or medicines. The UV radiation changes the genetic material (DNA) in cells and is, therefore, the main cause of skin cancer. The rate of new melanoma cases among both men and women has been increasing at 1.7% and 1.4% per year respectively, as per the data of Federal Centers for Disease Control and Prevention (CDC). Thus, the increasing prevalence of skin cancer is augmenting the growth of the market studied.

Scope of the Report

Ultraviolet radiation is a primary carcinogen that results in UV induced mutations, loss of activity in tumor suppressor genes, and the overexpression of oncogenes in keratinocytes, thus boosting the development of skin malignancies. The skin cancer diagnostics and therapeutics market comprise of various diagnostics and therapies related to skin cancer.

By Disease Type
Melanoma
Non-melanoma
By Diagnosis
Dermatoscopy
Skin Biopsy
Lymph Node Biopsy
Imaging Tests
Blood Tests
Others
By Treatment
Chemotherapy
Photodynamic Therapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Other Treatments
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Non-melanoma skin cancer segment is expected to witness healthy growth in the future

Currently, around 2-3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year. According to the World Cancer Research Fund International, in 2018, non-melanoma skin cancer is the fifth most commonly occurring cancer in people, with over one million diagnosis worldwide. Thus, it is the most common malignancy in the United States, with substantial associated morbidity and cost, as well as relatively small but significant mortality.

According to Cancer Research UK, there are around 147,000 new non-melanoma skin cancer cases in the United Kingdom every year, which is more than 400 every day (2014-2016). In 2016, around 67,700 new cases in females and 88,700 new cases in males have been registered.

Treatment for non-melanoma skin cancer is usually successful, as unlike the other types of cancer, there's a significantly lower risk that the cancer will spread to other parts of the body. Treatment for non-melanoma skin cancer is completely successful in approximately 90% of cases. Hence, the increasing rates of the non-melanoma skin cancer and its successful rates after treatment have helped in the growth of the overall market.

Skin Cancer Diagnostics Therapeutics Market Growth

North America dominates the Market and expected to do Same in the Forecast Period

North America is expected to dominate the market in the forecast period. As per the American Academy of Dermatology, skin cancer is the most common cancer in the United States. Most cases of melanoma, the deadliest kind of skin cancer, are caused by exposure to ultraviolet (UV) light. It is estimated that approximately 9,500 people in the United States are diagnosed with skin cancer every day. Furthermore, as per the estimates of the American Cancer Society, in 2018, there were around 91,270 new cases of melanoma in the United States, and approximately 9,320 deaths due to this disease.

Thus, the increasing incidences of skin cancer in the region is a major factor driving the growth of the market studied. Additionally, the recent advancements of skin cancer therapy, including photodynamic therapy (PDT), have been widely used in treating non-melanoma skin malignancies, thus boosting the growth of the market studied during the forecast period.

Skin Cancer Diagnostics Therapeutics Market Statistics

Competitive Landscape

The global skin cancer diagnostics and therapeutics market is highly competitive and consists of a number of major players. Companies, like Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., among others, hold the substantial market share in the skin cancer diagnostic & therapeutics market.

Major Players

  1. Amgen Inc.

  2. Bristol-Myers Squibb Company

  3. F. Hoffmann-La Roche Ltd

  4. Merck & Co., Inc.

  5. Sun Pharmaceutical Industries Ltd.

Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Skin Cancer

      2. 4.2.2 Rising Awareness about Skin Cancer

      3. 4.2.3 Extensive R&D Pipelines

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost Associated with Therapy

      2. 4.3.2 Side Effects and Complications Associated with Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Disease Type

      1. 5.1.1 Melanoma

      2. 5.1.2 Non-melanoma

    2. 5.2 By Diagnosis

      1. 5.2.1 Dermatoscopy

      2. 5.2.2 Skin Biopsy

      3. 5.2.3 Lymph Node Biopsy

      4. 5.2.4 Imaging Tests

      5. 5.2.5 Blood Tests

      6. 5.2.6 Others

    3. 5.3 By Treatment

      1. 5.3.1 Chemotherapy

      2. 5.3.2 Photodynamic Therapy

      3. 5.3.3 Immunotherapy

      4. 5.3.4 Targeted Therapy

      5. 5.3.5 Radiation Therapy

      6. 5.3.6 Other Treatments

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories.

      2. 6.1.2 Amgen, Inc.

      3. 6.1.3 Pfizer Inc.

      4. 6.1.4 Bristol-Myers Squibb Company

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 Sanofi SA

      7. 6.1.7 Merck & Co., Inc.

      8. 6.1.8 Novartis AG

      9. 6.1.9 Qiagen NV

      10. 6.1.10 Sun Pharmaceutical Industries Ltd.

      2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Skin Cancer Diagnostics and Therapeutics Market market is studied from 2018 - 2026.

The Skin Cancer Diagnostics and Therapeutics Market is growing at a CAGR of 10.4% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd. are the major companies operating in Skin Cancer Diagnostics and Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!